Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
8.73
+0.08 (0.92%)
At close: Dec 4, 2025, 4:00 PM EST
9.01
+0.28 (3.21%)
After-hours: Dec 4, 2025, 5:24 PM EST
Valneva SE Revenue
Valneva SE had revenue of 29.41M EUR in the quarter ending September 30, 2025, a decrease of -35.82%. This brings the company's revenue in the last twelve months to 179.91M, up 13.48% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
179.91M EUR
Revenue Growth
+13.48%
P/S Ratio
3.58
Revenue / Employee
252,331 EUR
Employees
713
Market Cap
756.22M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VALN News
- 8 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 8 days ago - Valneva to Further Consolidate its Operations in France - GlobeNewsWire
- 8 days ago - Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study - WSJ
- 8 days ago - Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate - GlobeNewsWire
- 14 days ago - Valneva SE (VALN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 weeks ago - Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate - GlobeNewsWire
- 5 weeks ago - Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences - GlobeNewsWire